Castration Resistance Accelerates Prostate Cancer Kinetics
Open Access
- 8 April 2026
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1021-1027
Abstract
Background: Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide efforts to determine optimal timing of therapy initiation. Despite the fact that castration has been used as therapy for prostate cancer for more than 70 years, no prior study has systematically quantified the effect of castration resistance on the rate of progression. The prostate‐specific antigen doubling time (PSADT) estimates prostate cancer kinetics and predicts overall survival, but whether PSADT changes as a result of castration resistance is not known. Methods: Here, we studied the longitudinal change in the PSADT before castration and following the development of castration resistance in a cohort of 40 patients with prostate cancer. Results: The PSADT of castration‐resistant prostate cancer (CR‐PSADT) was markedly shorter than the matched PSADT of castration‐naïve prostate cancer (CN‐PSADT) (median 2.6 months vs. 5.8 months, p < 0.001). The CR‐PSADT positively correlated with the CN‐PSADT and with overall survival. Sensitivity analysis suggested that the PSADT did not change as a function of time during progression when treatment was unchanged. Using a separate cohort of 36 patients with metastatic CRPC, we confirmed a positive correlation of CR‐PSADT with overall survival and identified a negative correlation with the Ki‐67 proliferation index of metastatic tumor biopsies. Conclusions: Castration‐resistant prostate cancer is associated with markedly accelerated disease kinetics compared with castration‐naïve prostate cancer. This acceleration of disease progression has the potential to shorten the survival of some patients with indolent disease who are treated prematurely with ADT.Keywords
Funding Information
- National Institutes of Health (K08CA273167)
- Prostate Cancer Foundation
This publication has 18 references indexed in Scilit:
- Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trialNature Communications, 2024
- Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate CancerNew England Journal of Medicine, 2023
- Automated Ki‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistryThe Journal of Pathology, 2023
- Sequencing Treatment for Castration-Resistant Prostate CancerCurrent Treatment Options in Oncology, 2016
- Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialThe Lancet Oncology, 2016
- Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up ResultsEuropean Urology, 2015
- Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up studyEuropean Journal of Cancer, 2015
- Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 studyThe Lancet Oncology, 2014
- Intermittent Androgen Suppression for Rising PSA Level after RadiotherapyNew England Journal of Medicine, 2012
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999